Export 22 results:
Author [ Title(Asc)] Type Year
Filters: Author is Mulligan, Mark J  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses., Vaccines (Basel), vol. 8, no. 1, 2019.
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1409-19, 2014.
R. B. Belshe, Frey, S. E., Graham, I., Mulligan, M. J., Edupuganti, S., Jackson, L. A., Wald, A., Poland, G., Jacobson, R., Keyserling, H. L., Spearman, P., Hill, H., and Wolff, M., Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant., J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
W. A. Keitel, Jackson, L. A., Edupuganti, S., Winokur, P. L., Mulligan, M. J., Thornburg, N. J., Patel, S. M., Rouphael, N. G., Lai, L., Bangaru, S., McNeal, M. M., Bellamy, A. R., and Hill, H. R., Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old., J Infect Dis, vol. 212, no. 4, pp. 552-61, 2015.
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial., Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
Y. - H. Chang, Duong, D. M., Goll, J. B., Wood, D. C., Jensen, T. L., Yin, L., Gelber, C. E., Seyfried, N. T., Anderson, E., Natrajan, M. S., Rouphael, N., Johnson, R. A., Sanz, P., Mulligan, M. J., and Hoft, D. F., Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine., Vaccines (Basel), vol. 8, no. 3, 2020.
E. J. Anderson, Lai, L., Wrammert, J., Kabbani, S., Xu, Y., Priyamvada, L., Hill, H., Goll, J. B., Jensen, T. L., Kao, C., Yildirim, I., Rouphael, N., Jackson, L., and Mulligan, M. J., Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine., Vaccines (Basel), vol. 8, no. 1, 2020.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations., Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
N. G. Rouphael, Hurwitz, S. J., Hart, M., Beck, A., Anderson, E. J., Deye, G., Osborn, B., Cai, S. Yi, Focht, C., Amegashie, C., Bowlin, T. L., Brooks, J., and Mulligan, M. J., Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers., Antimicrob Agents Chemother, vol. 63, no. 9, 2019.